Drug Type Small molecule drug |
Synonyms- |
Target |
Action inhibitors |
Mechanism Tubulin inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseSuspendedPhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Locally Advanced Pancreatic Adenocarcinoma | Phase 3 | United States | 16 Oct 2018 | |
Locally Advanced Pancreatic Adenocarcinoma | Phase 3 | France | 16 Oct 2018 | |
Locally Advanced Pancreatic Adenocarcinoma | Phase 3 | Hungary | 16 Oct 2018 | |
Locally Advanced Pancreatic Adenocarcinoma | Phase 3 | Israel | 16 Oct 2018 | |
Locally Advanced Pancreatic Adenocarcinoma | Phase 3 | Russia | 16 Oct 2018 | |
Locally Advanced Pancreatic Adenocarcinoma | Phase 3 | South Korea | 16 Oct 2018 | |
Locally Advanced Pancreatic Adenocarcinoma | Phase 3 | Taiwan Province | 16 Oct 2018 | |
Metastatic Pancreatic Cancer | Phase 3 | United States | 16 Oct 2018 | |
Metastatic Pancreatic Cancer | Phase 3 | France | 16 Oct 2018 | |
Metastatic Pancreatic Cancer | Phase 3 | Hungary | 16 Oct 2018 |
Phase 3 | 218 | (EndoTAG-1 and Gemcitabine) | tnqxzihdzt(knbpweathz) = mnjeqbdsru ngyfjqsutt (kkrehmyiyq, nvlansxbcx - uiootssewo) View more | - | 24 Mar 2023 | ||
(Gemcitabine Monotherapy) | tnqxzihdzt(knbpweathz) = uoxczfsyhw ngyfjqsutt (kkrehmyiyq, audrrzrqoi - okqqraxoet) View more | ||||||
Phase 3 | Pancreatic adenocarcinoma Second line | 218 | ybsigjuakq(yktraodtkc) = xzliflgtrm amtjxntoyg (rerugnqtwe ) View more | Negative | 03 Dec 2022 | ||
ybsigjuakq(yktraodtkc) = sfxhqrbnkk amtjxntoyg (rerugnqtwe ) View more |